Silence Therapeutics (NASDAQ:SLN) Releases Quarterly Earnings Results, Misses Expectations By $0.12 EPS

Silence Therapeutics (NASDAQ:SLN) issued its earnings results on Monday. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12), Zacks reports. Silence Therapeutics had a negative return on equity of 96.82% and a negative net margin of 8,943.86%.

Here are the key takeaways from Silence Therapeutics’ conference call:

• Divesiran met the SANRECO phase II primary endpoint, with 88% of treated patients maintaining hematocrit below 45% without phlebotomy versus 18% on placebo, a placebo-adjusted difference of nearly 70% (p<0.0001).
• Both dosing schedules produced robust responses, exceeding 80% in the Q12W arm and 90% in the Q6W arm; Silence plans to advance the less-frequent quarterly dosing regimen into phase III.
• Divesiran was generally well tolerated, with no new safety concerns, infrequent self-limiting injection-site reactions, and only two investigator-reported grade 1 anemia events; more than 90% of treated patients required no phlebotomies during weeks 0–36 versus 12.5% on placebo.
• Silence plans an end-of-phase II FDA meeting by year-end and aims to begin a registration-directed phase III study in the first half of 2027, but the final design, size, safety requirements, and potential Breakthrough Therapy application remain subject to regulatory discussions.

Silence Therapeutics Stock Down 4.9%

Shares of SLN opened at $14.67 on Wednesday. The company has a 50 day moving average of $9.66 and a two-hundred day moving average of $7.31. Silence Therapeutics has a twelve month low of $4.19 and a twelve month high of $17.58. The company has a market cap of $692.94 million, a price-to-earnings ratio of -11.46 and a beta of 1.39.

Analysts Set New Price Targets

A number of research analysts recently issued reports on SLN shares. HC Wainwright reiterated a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a research note on Wednesday, June 17th. Morgan Stanley upped their price target on shares of Silence Therapeutics from $25.00 to $32.00 and gave the company an “overweight” rating in a research note on Tuesday. Cantor Fitzgerald started coverage on Silence Therapeutics in a research note on Wednesday, June 24th. They issued an “overweight” rating for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Silence Therapeutics in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.50.

Institutional Trading of Silence Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Nantahala Capital Management LLC lifted its holdings in shares of Silence Therapeutics by 48.0% during the fourth quarter. Nantahala Capital Management LLC now owns 1,542,427 shares of the company’s stock worth $9,378,000 after purchasing an additional 500,000 shares during the period. Millennium Management LLC lifted its stake in Silence Therapeutics by 121.0% during the 4th quarter. Millennium Management LLC now owns 659,592 shares of the company’s stock valued at $4,010,000 after acquiring an additional 361,080 shares during the period. Opaleye Management Inc. acquired a new stake in Silence Therapeutics during the 4th quarter valued at approximately $480,000. UBS Group AG boosted its holdings in shares of Silence Therapeutics by 34.5% in the 3rd quarter. UBS Group AG now owns 307,363 shares of the company’s stock valued at $1,595,000 after acquiring an additional 78,854 shares during the last quarter. Finally, Marshall Wace LLP boosted its holdings in shares of Silence Therapeutics by 87.1% in the 4th quarter. Marshall Wace LLP now owns 155,680 shares of the company’s stock valued at $947,000 after acquiring an additional 72,461 shares during the last quarter. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.